Rafael pharmaceuticals announces successful completion of dose escalation with no dose-limiting toxicity (dlt) in first cohort of apollo 613 phase 1/2 clinical trial of cpi-613® (devimistat) in patients with relapsed clear cell sarcoma

Company will open additional sites and has begun enrolling patients in the second cohort of the trial company will open additional sites and has begun enrolling patients in the second cohort of the trial

RFL Ratings Summary

RFL Quant Ranking